Ipecacuanha: Difference between revisions
Rabin Bista (talk | contribs) No edit summary |
Rabin Bista (talk | contribs) No edit summary |
||
Line 6: | Line 6: | ||
|drugClass=OTC emetic | |drugClass=OTC emetic | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication= of Poisoning, acute by inducing vomiting | |indication= of [[Poisoning]], acute by inducing vomiting | ||
|adverseReactions=Diarrhea, Stomach cramps, Myalgia and Lethargy | |adverseReactions=[[Diarrhea]], [[Stomach cramps]], [[Myalgia]] and [[Lethargy]] | ||
Line 20: | Line 20: | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult=====Indications==== | |fdaLIADAdult=====Indications==== | ||
* Poisoning, acute<ref name="pmid2865374">{{cite journal| author=Krenzelok EP, Dean BS| title=Syrup of ipecac in children less than one year of age. | journal=J Toxicol Clin Toxicol | year= 1985 | volume= 23 | issue= 2-3 | pages= 171-6 | pmid=2865374 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2865374 }} </ref><ref name="pmid2900493">{{cite journal| author=Litovitz T| title=In defense of retaining ipecac syrup as an over-the-counter drug. | journal=Pediatrics | year= 1988 | volume= 82 | issue= 3 Pt 2 | pages= 514-6 | pmid=2900493 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2900493 }} </ref> | * [[Poisoning]], acute<ref name="pmid2865374">{{cite journal| author=Krenzelok EP, Dean BS| title=Syrup of ipecac in children less than one year of age. | journal=J Toxicol Clin Toxicol | year= 1985 | volume= 23 | issue= 2-3 | pages= 171-6 | pmid=2865374 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2865374 }} </ref><ref name="pmid2900493">{{cite journal| author=Litovitz T| title=In defense of retaining ipecac syrup as an over-the-counter drug. | journal=Pediatrics | year= 1988 | volume= 82 | issue= 3 Pt 2 | pages= 514-6 | pmid=2900493 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2900493 }} </ref> | ||
* to induce NAUSEA AND VOMITING | * to induce NAUSEA AND VOMITING | ||
====Dosage==== | ====Dosage==== | ||
(Adults / Children 2-18 years) | =====(Adults / Children 2-18 years)===== | ||
* Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional. | |||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
Line 37: | Line 38: | ||
====Dosage==== | ====Dosage==== | ||
(Adults / Children 2-18 years) | =====(Adults / Children 2-18 years)===== | ||
* Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional. | |||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
Line 47: | Line 49: | ||
<!--Warnings--> | <!--Warnings--> | ||
| | |warning=* Do not use if pellet-dispenser seal is broken. | ||
* Stop use and ask a doctor if symptoms persist more than 3 days or worsen. | |||
Do not use if pellet-dispenser seal is broken. | * If pregnant or breast-feeding, ask a health professional before use. | ||
Stop use and ask a doctor if symptoms persist more than 3 days or worsen. | * Keep out of reach of children. | ||
If pregnant or breast-feeding, ask a health professional before use. | |||
Keep out of reach of children. | |||
<!--Adverse Reactions--> | <!--Adverse Reactions--> | ||
<!--Clinical Trials Experience--> | <!--Clinical Trials Experience--> | ||
|clinicalTrials=* Diarrhea<ref name="pmid2860632">{{cite journal| author=Czajka PA, Russell SL| title=Nonemetic effects of ipecac syrup. | journal=Pediatrics | year= 1985 | volume= 75 | issue= 6 | pages= 1101-4 | pmid=2860632 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2860632 }} </ref> | |clinicalTrials=* [[Diarrhea]]<ref name="pmid2860632">{{cite journal| author=Czajka PA, Russell SL| title=Nonemetic effects of ipecac syrup. | journal=Pediatrics | year= 1985 | volume= 75 | issue= 6 | pages= 1101-4 | pmid=2860632 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2860632 }} </ref> | ||
* Stomach cramps | * [[Stomach cramps]] | ||
* Myalgia | * [[Myalgia]] | ||
* Lethargy<ref name="pmid2860632">{{cite journal| author=Czajka PA, Russell SL| title=Nonemetic effects of ipecac syrup. | journal=Pediatrics | year= 1985 | volume= 75 | issue= 6 | pages= 1101-4 | pmid=2860632 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2860632 }} </ref> | * [[Lethargy]]<ref name="pmid2860632">{{cite journal| author=Czajka PA, Russell SL| title=Nonemetic effects of ipecac syrup. | journal=Pediatrics | year= 1985 | volume= 75 | issue= 6 | pages= 1101-4 | pmid=2860632 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2860632 }} </ref> | ||
|drugInteractions= | |drugInteractions= | ||
Line 100: | Line 100: | ||
<!--Structure--> | <!--Structure--> | ||
|structure= | |structure======ACTIVE INGREDIENT HPUS===== | ||
IPECACUANHA 3X | IPECACUANHA 3X | ||
(Ipecac) | (Ipecac) | ||
INACTIVE INGREDIENTS | =====INACTIVE INGREDIENTS===== | ||
Lactose, sucrose. | Lactose, sucrose. | ||
Line 123: | Line 123: | ||
<!--How Supplied--> | <!--How Supplied--> | ||
|howSupplied= | |howSupplied= | ||
|storage=* Store at room temperature. | |storage=* Store at room temperature. | ||
|packLabel=====LABEL==== | |packLabel=====LABEL==== | ||
Line 132: | Line 132: | ||
<!--Patient Counseling Information--> | <!--Patient Counseling Information--> | ||
|fdaPatientInfo=QUESTIONS? | |fdaPatientInfo=* QUESTIONS? | ||
1-800-404-4666 | : 1-800-404-4666 | ||
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
Line 140: | Line 140: | ||
<!--Look-Alike Drug Names--> | <!--Look-Alike Drug Names--> | ||
|lookAlike= | |lookAlike= | ||
<!--Drug Shortage Status--> | <!--Drug Shortage Status--> | ||
Line 147: | Line 147: | ||
{{PillImage | {{PillImage | ||
|fileName=No image.jpg | |fileName=No image.jpg | ||
}} | }} | ||
<!--Pill Image--> | <!--Pill Image--> |
Revision as of 20:57, 16 February 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
Overview
Ipecacuanha is a OTC emetic that is FDA approved for the treatment of of Poisoning, acute by inducing vomiting. Common adverse reactions include Diarrhea, Stomach cramps, Myalgia and Lethargy.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
Dosage
(Adults / Children 2-18 years)
- Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ipecacuanha in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ipecacuanha in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Indications
- Poisoning, acute[1]
Dosage
(Adults / Children 2-18 years)
- Allow 3 or 4 pellets to dissolve in the mouth 3 times a day until symptoms are relieved or as directed by a health professional.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ipecacuanha in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ipecacuanha in pediatric patients.
Contraindications
There is limited information regarding Ipecacuanha Contraindications in the drug label.
Warnings
There is limited information regarding Ipecacuanha Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
Postmarketing Experience
There is limited information regarding Ipecacuanha Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Ipecacuanha Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
- If pregnant or breast-feeding, ask a health professional before use
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ipecacuanha in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Ipecacuanha during labor and delivery.
Nursing Mothers
- If pregnant or breast-feeding, ask a health professional before use
Pediatric Use
There is no FDA guidance on the use of Ipecacuanha with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Ipecacuanha with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Ipecacuanha with respect to specific gender populations.
Race
There is no FDA guidance on the use of Ipecacuanha with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Ipecacuanha in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Ipecacuanha in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Ipecacuanha in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Ipecacuanha in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
Monitoring
There is limited information regarding Monitoring of Ipecacuanha in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Ipecacuanha in the drug label.
Overdosage
There is limited information regarding Overdose of Ipecacuanha in the drug label.
Pharmacology
There is limited information regarding Ipecacuanha Pharmacology in the drug label.
Mechanism of Action
Structure
ACTIVE INGREDIENT HPUS
IPECACUANHA 3X
(Ipecac)
INACTIVE INGREDIENTS
Lactose, sucrose.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Ipecacuanha in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Ipecacuanha in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Ipecacuanha in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Ipecacuanha in the drug label.
How Supplied
There is limited information regarding Ipecacuanha How Supplied in the drug label.
Storage
- Store at room temperature.
Images
Drug Images
{{#ask: Page Name::Ipecacuanha |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
LABEL
Ingredients and Appearance
{{#ask: Label Page::Ipecacuanha |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
- QUESTIONS?
- 1-800-404-4666
Precautions with Alcohol
- Alcohol-Ipecacuanha interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- IPECACUANHA®[4]
Look-Alike Drug Names
There is limited information regarding Ipecacuanha Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ 1.0 1.1 Krenzelok EP, Dean BS (1985). "Syrup of ipecac in children less than one year of age". J Toxicol Clin Toxicol. 23 (2–3): 171–6. PMID 2865374.
- ↑ Litovitz T (1988). "In defense of retaining ipecac syrup as an over-the-counter drug". Pediatrics. 82 (3 Pt 2): 514–6. PMID 2900493.
- ↑ 3.0 3.1 Czajka PA, Russell SL (1985). "Nonemetic effects of ipecac syrup". Pediatrics. 75 (6): 1101–4. PMID 2860632.
- ↑ "Ipecacuanha pellet".
{{#subobject:
|Page Name=Ipecacuanha |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}} |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}